Connect with us

Legal & Regulation

New NIH and FDA Letter Reveals Federal Barriers to Marijuana Research

Jane Summers

Published

on

New NIH and FDA Letter Reveals Federal Barriers to Marijuana Research
- Ad -

The National Institute of Health (NIH) and the Food and Drug Administration (FDA) responded to a letter in which Senator Brian Schatz requested information on research and regulatory issues concerning therapeutic use of cannabis and cannabinoid compounds. Marijuana is illegal under federal law and is classified as a Schedule I substance. The illegality is known to hamper research. As an NPR article explains, “Because the federal government considers marijuana a Schedule 1 drug, research on marijuana or its active ingredients is highly restricted and even discouraged in some cases.”

The response letter reads that the “NIH also supports policy research on cannabis, including how it affects the use of other drugs.” Further, “The NIH and FDA strongly support the need for additional research on cannabis and its constituent compounds.” The organizations recognize the barriers.

The letter reads, “There are a variety of barriers to conducing research on cannabis and cannabinoids.”

It then points to issues, including that,

“under federal law, researchers are unable to purchase strains of marijuana or products containing marijuana from state dispensaries (even with non-federal funds), resulting in a significant gap in our understanding of these products on their impact on health. Licensing additional entities to supply marijuana may improve the diversity of research products that more closely reflect what is currently consumed.”

The letter continues, that the,

“continued placement of marijuana in Schedule I of the Controlled Substances Act creates significant administrative and cost challenges that slow this research and may deter scientists from pursuing cannabis research altogether.”

The NIH and FDA also “recommend streamlining the process for conducting research with cannabis and other Schedule I substances.”

All information is for general informational and educational purposes only. Nothing should be interpreted as legal or wellness advice.

Jane is a regular contributor who learned about the great benefits of CBD a few years ago after starting it herself. Impressed by its effects, she's interested in helping others learn about options that can be helpful for them.

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com